Brigatinib

Drug Profile

Brigatinib

Alternative Names: AP-26113

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics; Diamines; Piperazines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Epidermal growth factor receptor antagonists; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Non-small cell lung cancer
  • No development reported Lymphoma; Neuroblastoma

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 06 Feb 2017 Preregistration for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in European Union (PO)
  • 07 Dec 2016 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 17th World Conference on Lung Cancer (WCLC-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top